Fibrodysplasia ossificans progressiva (FOP) is one of the rarest and most disabling genetic conditions known. The University of Oxford is one of the few places in the world where this disease is being researched, with support from donations.
GMEC is pleased to announce the signing of the first collaborative research projects to be launched under theGMEC/Pfizer Rare Diseases agreement which was announced in 2014.
The University of Oxford and Pfizer have agreed three funded research projects in the fields of haematology and neuromuscular disorders. For additional information click here to see the announcement by University of Oxford.
A new Drug Discovery Institute in Oxford focusing on finding new medicines for Azheimer’s is being funded by Alzheimer’s Research UK. The SGC will play a major role in this Institute, providing our expertise in protein production, protein crystallography and medicinal chemistry.
Toronto, ON --Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.
The SGC-CHDI open access patent-free partnership for Huntington’s disease research has been selected as a featured Innovator to present on November 17th at the 6th annual Partnering for Cures meeting in New York City, NY. The conference will bring together nearly 1,000 medical research leaders, investors and decision-makers to forge the collaborations needed to speed and improve outcomes-driven R&D.
2014 is the International Year of Crystallography and to celebrate this event NDM has produced a series of short films.
‘Revolutionary Biology’: Revolutionary Biology shows how the field of structural biology has developed over the past 100 years, Oxford’s involvement in that development, and where we go from here.